GO:1990874 vascular associated smooth muscle cell proliferation: Disease Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990874 describes the multiplication or reproduction of vascular smooth muscle cells (VSMCs), the non-striated, elongated, spindle-shaped cells lining blood vessels.
• VSMC proliferation is a hallmark of vascular remodeling and drives diseases such as aortic aneurysm, dissection, atherosclerosis, and restenosis after injury.
• Phenotypic switching of VSMCs from a contractile to a synthetic, proliferative state is a central mechanism in neointimal hyperplasia and vascular disease.
• Key molecular regulators include ACTA2, NEXN, ALDH2, ATF3, RBM24, and JAK2, which control VSMC proliferation, migration, and fate.
• Human genetic studies link coronary artery disease-associated variants to altered VSMC gene expression, highlighting the clinical relevance of this process.
• Clonal expansion of VSMCs in cardiovascular disease can be oligoclonal, suggesting diverse origins and therapeutic targeting opportunities.
Description
Vascular associated smooth muscle cell proliferation (GO:1990874) is the biological process by which vascular smooth muscle cells (VSMCs) multiply, leading to expansion of the VSMC population within blood vessel walls. VSMCs are non-striated, elongated, spindle-shaped cells that line blood vessels and are essential for vascular tone and structural integrity. Under pathological conditions, VSMCs can switch from a quiescent, contractile phenotype to a proliferative, synthetic phenotype, a process known as phenotypic switching. This switch is a critical driver of vascular remodeling in diseases such as aortic aneurysm, dissection, atherosclerosis, and restenosis after angioplasty. Understanding the molecular mechanisms that govern VSMC proliferation is therefore of major interest for developing targeted therapies. Recent studies have identified numerous genes and signaling pathways that regulate VSMC proliferation, including ACTA2, NEXN, ALDH2, ATF3, RBM24, and JAK2. These findings underscore the importance of GO:1990874 in cardiovascular biology and disease.
vascular associated smooth muscle cell proliferation At A Glance
| GO ID | GO:1990874 |
|---|---|
| GO term | vascular associated smooth muscle cell proliferation |
| Ontology | biological_process |
| Synonym | vascular smooth muscle cell proliferation; VSMC proliferation |
| Definition | The multiplication or reproduction of vascular smooth muscle cells, resulting in the expansion of a cell population. |
| Cell type | Vascular smooth muscle cell (non-striated, elongated, spindle-shaped cell lining blood vessels) |
| Major function | Expansion of VSMC population during vascular remodeling, development, and disease |
| Related diseases | Aortic aneurysm, dissection, atherosclerosis, restenosis, coronary artery disease |
| Research relevance | Target for therapies aimed at preventing pathological vascular remodeling |
What Is GO:1990874?
GO:1990874, vascular associated smooth muscle cell proliferation, is defined as the multiplication or reproduction of vascular smooth muscle cells, resulting in the expansion of a cell population. A vascular smooth muscle cell is a non-striated, elongated, spindle-shaped cell found lining the blood vessels. This process is synonymous with VSMC proliferation and is a biological process ontology term.
Why Is vascular associated smooth muscle cell proliferation Important in Cell Biology?
GO:1990874 is critically important because dysregulated VSMC proliferation is a central pathological mechanism in major cardiovascular diseases, including aortic aneurysms, dissections, atherosclerosis, and restenosis after vascular injury. VSMC proliferation also contributes to neointimal hyperplasia following angioplasty or stenting, a leading cause of restenosis. Moreover, human genetic studies have linked coronary artery disease-associated variants to altered VSMC gene expression, demonstrating that this process is directly relevant to human disease susceptibility. Understanding the molecular regulation of VSMC proliferation can reveal new therapeutic targets and biomarkers for cardiovascular disease.
• VSMC proliferation is a hallmark of vascular remodeling in aortic aneurysm and dissection.
• It drives neointimal hyperplasia and restenosis after vascular injury or intervention.
• Phenotypic switching of VSMCs from contractile to synthetic/proliferative state is a key mechanism in atherosclerosis.
• ACTA2 variants associated with aortopathy cause dysregulated VSMC proliferation and gene expression.
• ALDH2 deficiency aggravates restenosis by enhancing VSMC proliferation via glutamine uptake.
• ATF3 expression spatiotemporally determines VSMC fate in abdominal aortic aneurysm.
• RBM24 regulates VSMC phenotypic switching by stabilizing JAK2 mRNA.
• Coronary artery disease-associated variants regulate VSMC gene expression, linking genetics to proliferation.
• Oligoclonal VSMC expansion in cardiovascular disease suggests multiple origins and complex clonal dynamics.
• Targeting VSMC proliferation pathways offers therapeutic potential for preventing vascular disease progression.
What Happens During vascular associated smooth muscle cell proliferation?
Initiation and Phenotypic Switching
In simple terms: VSMCs change from a quiet, contractile state to a growing, synthetic state.
In response to vascular injury or pathological stimuli, VSMCs undergo phenotypic switching from a contractile, quiescent phenotype to a synthetic, proliferative phenotype. This switch is characterized by downregulation of contractile markers such as ACTA2 and upregulation of synthetic markers. NEXN has been shown to regulate this phenotypic switching and neointimal hyperplasia. Similarly, RBM24 regulates VSMC phenotypic switching by stabilizing JAK2 mRNA. This initiation step is critical for subsequent proliferation and migration.
Cell Cycle Entry and Proliferation
In simple terms: The switched VSMCs start dividing rapidly, increasing their numbers.
Once VSMCs adopt a synthetic phenotype, they re-enter the cell cycle and proliferate. This proliferation is driven by growth factors, cytokines, and signaling pathways. ALDH2 deficiency enhances VSMC proliferation through SLC38A2-mediated upregulation of glutamine uptake, contributing to restenosis. ATF3 expression spatiotemporally determines VSMC fate in abdominal aortic aneurysm, influencing proliferation and apoptosis. ACTA2 variants associated with aortopathy lead to dysregulated VSMC proliferation and gene expression. These studies highlight diverse molecular drivers of VSMC proliferation.
Migration and Neointima Formation
In simple terms: The growing VSMCs move into the inner layer of the vessel, causing narrowing.
Proliferating VSMCs migrate from the media to the intima, where they contribute to neointimal hyperplasia. NEXN regulates VSMC phenotypic switching and neointimal hyperplasia, indicating a role in migration and intimal thickening. In restenosis, ALDH2 deficiency aggravates vascular injury-induced restenosis by enhancing VSMC proliferation. This migration and accumulation of VSMCs narrow the vessel lumen, leading to clinical complications.
Clonal Expansion and Heterogeneity
In simple terms: Not all VSMCs are the same; some clones expand more than others.
Recent evidence indicates that VSMC expansion in cardiovascular disease can be oligoclonal, meaning that a limited number of VSMC clones undergo expansion. This suggests that distinct subpopulations of VSMCs may have different proliferative capacities. Cellular mechanisms of oligoclonal VSMC expansion involve multiple factors, including genetic and epigenetic changes. Understanding clonal dynamics is important for targeting pathological VSMC proliferation.
Resolution or Pathological Persistence
In simple terms: Sometimes the growth stops, but in disease it continues and causes damage.
In normal vascular repair, VSMC proliferation is transient and resolves. However, in pathological conditions such as atherosclerosis, aneurysm, or restenosis, proliferation persists, leading to vessel wall remodeling and clinical events. ATF3 expression determines VSMC fate, with sustained proliferation contributing to abdominal aortic aneurysm. Coronary artery disease-associated variants can sustain VSMC gene expression changes that promote disease. Thus, failure to resolve VSMC proliferation is a key pathological feature.
Key Genes Involved in GO:1990874 vascular associated smooth muscle cell proliferation
The following genes and proteins have been experimentally implicated in the regulation of vascular associated smooth muscle cell proliferation (GO:1990874).
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACTA2 | Contractile VSMC marker; variants cause aortopathy with dysregulated proliferation | ACTA2 variant-associated aortopathy model |
| NEXN | Regulates VSMC phenotypic switching and neointimal hyperplasia | Knockout studies in vascular injury models |
| ALDH2 | Deficiency enhances VSMC proliferation via SLC38A2-mediated glutamine uptake | Restenosis after vascular injury |
| ATF3 | Spatiotemporal expression determines VSMC fate in abdominal aortic aneurysm | VSMC fate and aneurysm progression |
| RBM24 | Stabilizes JAK2 mRNA to regulate VSMC phenotypic switching | Vascular remodeling |
| JAK2 | Signaling kinase stabilized by RBM24; promotes VSMC phenotypic switching | Downstream effector in VSMC proliferation |
| SLC38A2 | Glutamine transporter upregulated by ALDH2 deficiency; enhances VSMC proliferation | Metabolic regulation of VSMC proliferation |
| MYH11 | Contractile VSMC marker; loss associated with phenotypic switching | VSMC phenotype studies |
| CNN1 | Calponin, contractile marker; downregulated in synthetic VSMCs | VSMC phenotypic switching |
| PCNA | Proliferation marker; indicates VSMC cell cycle entry | Proliferation assays |
| Ki-67 | Proliferation marker; used to quantify VSMC proliferation | Immunohistochemistry in vascular tissues |
| MMP2 | Matrix metalloproteinase; involved in VSMC migration and vascular remodeling | Aortic aneurysm and dissection |
| MMP9 | Matrix metalloproteinase; contributes to extracellular matrix degradation | Vascular remodeling |
| IL-6 | Inflammatory cytokine; promotes VSMC proliferation | Inflammation-driven VSMC proliferation |
| PDGF-BB | Growth factor; potent mitogen for VSMCs | VSMC proliferation assays |
| TGF-β | Cytokine; context-dependent effects on VSMC proliferation | VSMC phenotypic modulation |
| Angiotensin II | Vasoactive peptide; promotes VSMC proliferation and vascular remodeling | Hypertension and aneurysm models |
| Notch3 | Signaling receptor; regulates VSMC differentiation and proliferation | Vascular development and disease |
How Is vascular associated smooth muscle cell proliferation Regulated?
VSMC proliferation is regulated by a complex network of signaling pathways, transcription factors, and epigenetic modifiers. Key regulators include growth factor signaling (e.g., PDGF-BB), inflammatory cytokines (e.g., IL-6), and metabolic pathways (e.g., glutamine uptake via SLC38A2). ATF3 acts as a spatiotemporal determinant of VSMC fate, influencing proliferation and apoptosis in abdominal aortic aneurysm. RBM24 stabilizes JAK2 mRNA, thereby regulating VSMC phenotypic switching and proliferation. ALDH2 deficiency enhances VSMC proliferation through SLC38A2-mediated upregulation of glutamine uptake, linking metabolic stress to restenosis. Additionally, coronary artery disease-associated genetic variants can regulate VSMC gene expression, affecting proliferative capacity. These regulatory mechanisms are potential therapeutic targets for modulating VSMC proliferation in vascular disease.
vascular associated smooth muscle cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACTA2 | Aortic aneurysm and dissection | ACTA2 variant knock-in mouse or human VSMC line |
| ALDH2 | Restenosis after vascular injury | ALDH2 knockout mouse with carotid artery injury |
| ATF3 | Abdominal aortic aneurysm | VSMC-specific ATF3 knockout or overexpression mouse |
| RBM24 | Vascular remodeling and atherosclerosis | RBM24 knockout or knockdown in VSMCs |
| NEXN | Neointimal hyperplasia | NEXN knockout mouse with vascular injury |
Aortic Aneurysm and Dissection
VSMC proliferation is a critical process in the pathogenesis of aortic aneurysms and dissections. Dysregulated VSMC proliferation and gene expression underlie ACTA2 variant-associated aortopathy. ATF3 expression spatiotemporally determines VSMC fate in abdominal aortic aneurysm, with sustained proliferation contributing to disease progression. The role of VSMCs in the development of aortic aneurysms and dissections has been extensively reviewed, highlighting proliferation, apoptosis, and phenotypic switching as key mechanisms. Targeting VSMC proliferation may offer therapeutic benefits for these life-threatening conditions.
Restenosis After Vascular Injury
Restenosis is a major complication after angioplasty or stenting, characterized by neointimal hyperplasia due to VSMC proliferation and migration. ALDH2 deficiency aggravates vascular injury-induced restenosis by enhancing VSMC proliferation through SLC38A2-mediated upregulation of glutamine uptake. NEXN regulates VSMC phenotypic switching and neointimal hyperplasia, further implicating VSMC proliferation in restenosis. These findings suggest that targeting metabolic or phenotypic switching pathways could prevent restenosis.
Atherosclerosis and Coronary Artery Disease
VSMC proliferation contributes to atherosclerotic plaque stability and progression. Coronary artery disease-associated variants regulate VSMC gene expression, linking genetic susceptibility to VSMC proliferation. RBM24 regulates VSMC phenotypic switching by stabilizing JAK2 mRNA, a process relevant to vascular remodeling in atherosclerosis. Oligoclonal VSMC expansion in cardiovascular disease suggests that specific VSMC clones drive plaque growth. Understanding these mechanisms may lead to new treatments for atherosclerosis.
From vascular associated smooth muscle cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate VSMC proliferation in vivo? | VSMC-specific knockout mouse (e.g., Cre-loxP) |
| Does a specific point mutation in gene X affect VSMC proliferation? | Point-mutation knock-in mouse or human VSMC line |
| Does overexpression of gene X promote VSMC proliferation? | Adenovirus or lentivirus-mediated overexpression in VSMCs |
| Does tagging of gene X affect its function in VSMC proliferation? | Tagged knock-in (e.g., FLAG, GFP) in VSMCs |
| What is the role of gene X in neointimal hyperplasia? | Vascular injury model (e.g., carotid artery ligation) in knockout mice |
| Can CRISPR library screening identify novel regulators of VSMC proliferation? | Genome-wide CRISPR knockout or activation screen in human VSMCs |
How to Study the vascular associated smooth muscle cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify proliferation-associated genes in VSMCs |
| ATAC-seq | Chromatin accessibility | Map regulatory variants affecting VSMC gene expression |
| EdU incorporation | DNA synthesis (proliferation) | Quantify VSMC proliferation in vitro |
| Ki-67 staining | Proliferation marker | Assess VSMC proliferation in tissues |
| Western blot | Protein expression and phosphorylation | Measure contractile and synthetic markers |
| Immunohistochemistry | Protein localization in tissues | Detect VSMC proliferation in neointima |
| CRISPR knockout | Gene function loss | Test candidate gene role in VSMC proliferation |
| CRISPR activation | Gene overexpression | Screen for genes that promote VSMC proliferation |
Transcriptomic and Epigenomic Profiling
RNA sequencing (RNA-seq) and chromatin accessibility assays (ATAC-seq) are used to profile gene expression and regulatory elements in proliferating VSMCs. Coronary artery disease-associated variants have been shown to regulate VSMC gene expression using these methods. RBM24 regulation of JAK2 mRNA stability was studied using RNA immunoprecipitation and RNA-seq. These techniques help identify key drivers of VSMC proliferation.
Proliferation Assays
VSMC proliferation is commonly measured using EdU incorporation, Ki-67 staining, or cell counting. ALDH2 deficiency was shown to enhance VSMC proliferation using these assays. ATF3 effects on VSMC fate were assessed by proliferation and apoptosis assays. These methods are essential for quantifying the proliferative response.
Genetic and Pharmacological Manipulation
Knockout, knockdown, and overexpression of candidate genes in VSMCs are used to test causality. NEXN knockout and overexpression studies demonstrated its role in phenotypic switching and neointimal hyperplasia. ACTA2 variant knock-in models revealed dysregulated VSMC proliferation. These approaches are fundamental for mechanistic studies.
In Vivo Vascular Injury Models
Animal models of vascular injury, such as carotid artery ligation or wire injury, are used to study VSMC proliferation in restenosis and neointimal hyperplasia. ALDH2 knockout mice subjected to vascular injury showed aggravated restenosis. NEXN knockout mice exhibited neointimal hyperplasia. These models provide physiological relevance.
How CRISPR Can Be Used to Study GO:1990874 vascular associated smooth muscle cell proliferation
Knockout
CRISPR knockout is used to delete candidate genes in VSMCs to determine their necessity for proliferation. For example, NEXN knockout in VSMCs led to altered phenotypic switching and neointimal hyperplasia. ALDH2 knockout mice exhibited enhanced VSMC proliferation and aggravated restenosis. These studies demonstrate the power of CRISPR knockout for identifying essential regulators of GO:1990874.
Point Mutation
CRISPR point mutation introduces specific disease-associated variants into the genome to study their effects on VSMC proliferation. ACTA2 variants associated with aortopathy were modeled using point mutations, revealing dysregulated VSMC proliferation and gene expression. This approach is crucial for understanding how genetic variants contribute to vascular disease.
Knock-in
CRISPR knock-in is used to insert tags, reporters, or human disease alleles into the genome. Tagged knock-in of RBM24 or JAK2 could help track their localization and interactions in VSMCs. Knock-in of coronary artery disease risk variants can reveal their impact on VSMC gene expression. This technique enables precise modeling of human genetic variation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression is used to increase gene expression in VSMCs. Overexpression of ATF3 or RBM24 can promote or inhibit VSMC proliferation, depending on context. Overexpression studies help establish sufficiency of a gene in driving GO:1990874. These models are valuable for target validation.
How EDITGENE Supports vascular associated smooth muscle cell proliferation Research
Researchers studying vascular associated smooth muscle cell proliferation-related genes often need to determine whether a candidate gene is causally involved in VSMC proliferation, phenotypic switching, or vascular remodeling. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for vascular associated smooth muscle cell proliferation research.
Frequently Asked Questions About vascular associated smooth muscle cell proliferation
What is GO:1990874?
GO:1990874 is the Gene Ontology term for vascular associated smooth muscle cell proliferation, defined as the multiplication or reproduction of vascular smooth muscle cells, resulting in expansion of a cell population.
What are vascular smooth muscle cells?
Vascular smooth muscle cells (VSMCs) are non-striated, elongated, spindle-shaped cells found lining blood vessels, responsible for vascular tone and remodeling.
What genes are involved in vascular associated smooth muscle cell proliferation?
Key genes include ACTA2, NEXN, ALDH2, ATF3, RBM24, JAK2, and SLC38A2, among others.
How is VSMC proliferation measured?
VSMC proliferation is measured using EdU incorporation, Ki-67 staining, cell counting, and proliferation markers.
What diseases are associated with VSMC proliferation?
VSMC proliferation is associated with aortic aneurysm, dissection, atherosclerosis, restenosis, and coronary artery disease.
What is phenotypic switching in VSMCs?
Phenotypic switching is the transition of VSMCs from a contractile, quiescent state to a synthetic, proliferative state, driven by factors such as NEXN and RBM24.
How does ALDH2 affect VSMC proliferation?
ALDH2 deficiency enhances VSMC proliferation through SLC38A2-mediated upregulation of glutamine uptake, aggravating restenosis.
What is the role of ATF3 in VSMC proliferation?
ATF3 expression spatiotemporally determines VSMC fate in abdominal aortic aneurysm, influencing proliferation and apoptosis.
Can CRISPR be used to study VSMC proliferation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to study genes regulating VSMC proliferation.
What models are used to study VSMC proliferation in vivo?
Common models include VSMC-specific knockout mice, vascular injury models (e.g., carotid artery ligation), and aneurysm models.
Conclusion
GO:1990874, vascular associated smooth muscle cell proliferation, is a fundamental biological process that underlies vascular remodeling in health and disease. Dysregulated VSMC proliferation contributes to aortic aneurysm, dissection, atherosclerosis, and restenosis, making it a critical therapeutic target. Recent advances have identified key molecular regulators such as ACTA2, NEXN, ALDH2, ATF3, RBM24, and JAK2, providing new insights into the mechanisms of VSMC proliferation. Continued research using CRISPR-based models and high-throughput screening will further elucidate these pathways and facilitate the development of targeted therapies. EDITGENE offers comprehensive services to support this research.
References
- 1. Pepin ME et al.. 2025. Dysregulated smooth muscle cell proliferation and gene expression underlie ACTA2 variant-associated aortopathy.. Am J Physiol Heart Circ Physiol 329(5):H1072-H1079 PMID: 41021763
- 2. Rombouts KB et al.. 2022. The role of vascular smooth muscle cells in the development of aortic aneurysms and dissections.. Eur J Clin Invest 52(4):e13697 PMID: 34698377
- 3. Lin Z et al.. 2025. NEXN regulates vascular smooth muscle cell phenotypic switching and neointimal hyperplasia.. JCI Insight 10(13) PMID: 40440261
- 4. Hou D et al.. 2026. ALDH2 deficiency aggravates vascular injury-induced restenosis by enhancing vascular smooth muscle cell proliferation through SLC38A2-mediated upregulation of glutamine uptake.. Metabolism 174:156411 PMID: 41067488
- 5. Wen Y et al.. 2024. Spatiotemporal ATF3 Expression Determines VSMC Fate in Abdominal Aortic Aneurysm.. Circ Res 134(11):1495-1511 PMID: 38686580
- 6. Zhang H et al.. 2025. RBM24 regulates phenotypic switching of smooth muscle cell in vascular remodeling by stabilizing JAK2 mRNA.. Cardiovasc Res 121(17):2791-2808 PMID: 41216933
- 7. Barbera N et al.. 2025. Coronary artery disease-associated variants regulate vascular smooth muscle cell gene expression.. Nat Cardiovasc Res 4(10):1295-1310 PMID: 41057608
- 8. Worssam MD et al.. 2023. Cellular mechanisms of oligoclonal vascular smooth muscle cell expansion in cardiovascular disease.. Cardiovasc Res 119(5):1279-1294 PMID: 35994249
